Abstract:The induction of an effective immune response is critical for the success of mRNA-based therapeutics. Here, we developed a nanoadjuvant system compromised of Quil-A and DOTAP (dioleoyl 3 trimethylammonium propane), hence named QTAP, for the efficient delivery of mRNA vaccine constructs into cells. Electron microscopy indicated that the complexation of mRNA with QTAP forms nanoparticles with an average size of 75 nm and which have ~90% encapsulation efficiency. The incorporation of pseudouridine-modified mRNA resulted in higher transfection efficiency and protein translation with low cytotoxicity than unmodified mRNA. When QTAP-mRNA or QTAP alone transfected macrophages, pro-inflammatory pathways (e.g., NLRP3, NF-kb, and MyD88) were upregulated, an indication of macrophage activation. In C57Bl/6 mice, QTAP nanovaccines encoding Ag85B and Hsp70 transcripts (QTAP-85B+H70) were able to elicit robust IgG antibody and IFN- ɣ, TNF-α, IL-2, and IL-17 cytokines responses. Following aerosol challenge with a clinical isolate of M. avium ss. hominissuis (M.ah), a significant reduction of mycobacterial counts was observed in lungs and spleens of only immunized animals at both 4- and 8-weeks post-challenge. As expected, reduced levels of M. ah were associated with diminished histological lesions and robust cell-mediated immunity. Interestingly, polyfunctional T-cells expressing IFN- ɣ, IL-2, and TNF- α were detected at 8 but not 4 weeks post-challenge. Overall, our analysis indicated that QTAP is a highly efficient transfection agent and could improve the immunogenicity of mRNA vaccines against pulmonary M. ah, an infection of significant public health importance, especially to the elderly and to those who are immune compromised.

Short Carbon Nanotube-Based Delivery of mRNA for HIV-1 Vaccines

Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

Technological challenges in the preclinical development of an HIV nanovaccine candidate

Nanotechnology-based mRNA vaccines

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity

A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines

Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems

Mucosal Delivery of HIV‐1 Glycoprotein Vaccine Candidate Enabled by Short Carbon Nanotubes

Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis

Nanoparticle Technology for Mrna: Delivery Strategy, Clinical Application and Developmental Landscape

mRNA-based HIV-1 vaccines

Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines

mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice

Design and Characterization of a New Formulation for the Delivery of COVID-19-mRNA Vaccine to the Nasal Mucosa

Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity

Computationally designed mRNA-launched protein nanoparticle vaccines

Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform

Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines

Cationic Lipid-Assisted Nanoparticles for Delivery of Mrna Cancer Vaccine.